Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Denali Therapeutics Inc
(NQ:
DNLI
)
24.22
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Denali Therapeutics Inc
< Previous
1
2
3
Next >
Denali Therapeutics Stock Is Sliding After The Bell: Here's Why
October 10, 2024
Denali Therapeutics shares are moving lower in Thursday's after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued.
Via
Benzinga
A Biotech Breakout Will Be Led By Small Caps
September 23, 2024
It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever.
Via
Talk Markets
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q2 2024
August 01, 2024
DNLI stock results show that Denali Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Denali Therapeutics Stock Gets Technical Rating Upgrade
July 16, 2024
Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Via
Investor's Business Daily
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
July 08, 2024
Longevity stocks are at the forefront of combating age-related illnesses with transformative AI-driven drug discovery.
Via
InvestorPlace
4 Analysts Assess Denali Therapeutics: What You Need To Know
February 28, 2024
Via
Benzinga
Denali Therapeutics: Q4 Earnings Insights
February 27, 2024
Via
Benzinga
The Latest Analyst Ratings for Denali Therapeutics
December 13, 2023
Via
Benzinga
Where Denali Therapeutics Stands With Analysts
November 08, 2023
Via
Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
June 03, 2024
Via
Benzinga
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
May 08, 2024
Via
Benzinga
DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024
May 07, 2024
DNLI stock results show that Denali Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Analyst Expectations for Denali Therapeutics's Future
August 31, 2023
Via
Benzinga
Where Denali Therapeutics Stands With Analysts
August 10, 2023
Via
Benzinga
Analyst Expectations for Denali Therapeutics's Future
June 21, 2023
Within the last quarter, Denali Therapeutics (NASDAQ:DNLI) has observed the following analyst ratings:
Via
Benzinga
To the Moon and Beyond: 7 Stocks With Cosmic Potential
March 14, 2024
With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential.
Via
InvestorPlace
Goldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To Know
February 29, 2024
Via
Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 27, 2024
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.
Via
Benzinga
Why Shares of Denali Therapeutics Are Up Monday
May 15, 2023
Analysts maintained their buy ratings on the clinical-stage biotech company.
Via
The Motley Fool
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
February 27, 2024
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
February 12, 2024
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer.
Via
Benzinga
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
February 08, 2024
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month.
Via
InvestorPlace
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
January 02, 2024
Biotech stocks targeting longevity could uncover the fountain of youth in coming years, offering a prime investment opportunity today.
Via
InvestorPlace
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
November 03, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst
September 06, 2023
B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a
Via
Benzinga
Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now
June 29, 2023
With longevity back in the news, many investors are wondering which biotech stocks to buy to best cash in on the growing trend.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
September 06, 2023
Via
Benzinga
Denali Says Hunter Syndrome Candidate Lowers Disease-Associated Biomarker
June 20, 2023
Denali Therapeutics Inc (NASDAQ: DNLI) announced new interim results from the ongoing open-label, single-arm Phase 1/2 study of DNL310 IDS in children with
Via
Benzinga
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure
June 05, 2023
Via
Benzinga
Biogen Moves Deeper In Alzheimer's With Denali
April 14, 2023
Biogen exercised their rights to a Denali Alzheimer's drug. What does this mean longer term to the field and the companies?
Via
Talk Markets
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.